SG162798A1 - Liquid pharmaceutical formulations of docetaxel - Google Patents

Liquid pharmaceutical formulations of docetaxel

Info

Publication number
SG162798A1
SG162798A1 SG201004237-2A SG2010042372A SG162798A1 SG 162798 A1 SG162798 A1 SG 162798A1 SG 2010042372 A SG2010042372 A SG 2010042372A SG 162798 A1 SG162798 A1 SG 162798A1
Authority
SG
Singapore
Prior art keywords
docetaxel
liquid pharmaceutical
pharmaceutical formulations
liquid
parenteral administration
Prior art date
Application number
SG201004237-2A
Other languages
English (en)
Inventor
Aikun Julie Liu
Allan Harvey Spencer
Andrew Malcolm Knill
Daniel David Ash
Original Assignee
Hospira Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2005903196A external-priority patent/AU2005903196A0/en
Application filed by Hospira Australia Pty Ltd filed Critical Hospira Australia Pty Ltd
Publication of SG162798A1 publication Critical patent/SG162798A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG201004237-2A 2005-06-17 2006-06-16 Liquid pharmaceutical formulations of docetaxel SG162798A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2005903196A AU2005903196A0 (en) 2005-06-17 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
SG162798A1 true SG162798A1 (en) 2010-07-29

Family

ID=37531888

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201004237-2A SG162798A1 (en) 2005-06-17 2006-06-16 Liquid pharmaceutical formulations of docetaxel

Country Status (9)

Country Link
US (2) US20090118354A1 (de)
EP (3) EP1904052A4 (de)
JP (1) JP2008543789A (de)
KR (1) KR20080030024A (de)
CA (1) CA2611592A1 (de)
IL (1) IL187957A0 (de)
SG (1) SG162798A1 (de)
TW (1) TW200800159A (de)
WO (1) WO2006133510A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI417114B (zh) 2005-08-31 2013-12-01 Abraxis Bioscience Llc 具有增強穩定性之弱水溶性藥物之組合物及其製備方法
CN101291658B (zh) * 2005-08-31 2014-04-16 阿布拉科斯生物科学有限公司 用于制备稳定性增加的水难溶性药物的组合物和方法
BRPI0600194A (pt) 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
CN101023940A (zh) * 2006-02-20 2007-08-29 郝守祝 一种紫杉烷类化合物的药用组合物、制备方法及用途
EP1946747A1 (de) * 2007-01-17 2008-07-23 Sandoz AG Taxanderivat enthaltende pharmazeutische Zusammensetzung von verbesserter Stabilität
WO2009047794A2 (en) * 2007-10-01 2009-04-16 Intas Pharmaceuticals Limited Taxane derivative composition
CA2710525C (en) 2007-12-24 2017-08-22 Sun Pharma Advanced Research Company Limited Nanodispersion
KR101053780B1 (ko) * 2008-02-29 2011-08-02 동아제약주식회사 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
DE102008059201A1 (de) * 2008-11-27 2010-06-02 GÖPFERICH, Achim, Prof. Dr. In situ präzipitierende Arzneistofflösungen
KR20120050414A (ko) 2009-06-19 2012-05-18 썬 파마 어드밴스트 리서치 컴패니 리미티드 약물의 나노분산액 및 그의 제조 방법
JP5568272B2 (ja) * 2009-09-29 2014-08-06 テルモ株式会社 ヨウ素配合脂溶性ビタミン含有液
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US8476310B2 (en) 2009-10-19 2013-07-02 Scidose Llc Docetaxel formulations with lipoic acid
CN102038635A (zh) 2009-10-23 2011-05-04 天津天士力集团有限公司 一种含有pH值调节剂的紫杉烷类药物溶液及其制备方法
MX341082B (es) 2010-05-03 2016-08-08 Teikoku Pharma Usa Inc Formulaciones de pro-emulsion de taxano no acuosas y metodos para hacer y usar las mismas.
TWI511725B (zh) * 2010-11-10 2015-12-11 Tasly Holding Group Co Ltd A taxane-containing drug solution containing chelating agent and a preparation method thereof
WO2013024495A1 (en) * 2011-08-18 2013-02-21 Dr. Reddys Laboratories Limited Pharmaceutical formulations of cabazitaxel
JP2013194009A (ja) * 2012-03-21 2013-09-30 Nipro Corp ドセタキセル製剤
ES2687705T3 (es) * 2012-07-19 2018-10-26 Fujifilm Corporation Composición líquida que contiene un principio activo a base de taxano, proceso de producción de la misma y preparación medicinal líquida
US9012665B2 (en) 2012-07-31 2015-04-21 Yung Shin Pharm. Ind. Co., Ltd. Amorphous cabazitaxel
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
CN103169651B (zh) * 2012-12-26 2018-01-19 辰欣药业股份有限公司 一种含多西他赛的注射剂及其制备方法
JP6076744B2 (ja) * 2013-01-04 2017-02-08 ナガセ医薬品株式会社 ドセタキセル含有医薬組成物
EP2777691A1 (de) 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoid - Reinigung der flüssigen Hilfsstoffen
CN104546694A (zh) * 2013-10-15 2015-04-29 悦康药业集团有限公司 一种多西他赛注射液及其制备方法
CN103626661B (zh) * 2013-12-10 2015-03-18 重庆泰濠制药有限公司 一种化合物及其应用、制备方法
EA024176B1 (ru) * 2014-03-05 2016-08-31 Республиканское Унитарное Производственное Предприятие "Белмедпрепараты" (Руп "Белмедпрепараты") Способ получения противоопухолевого препарата на основе доцетаксела
US20160120742A1 (en) * 2014-11-04 2016-05-05 Sandoz Ag Compositions including cabazitaxel
TWI752750B (zh) 2015-09-30 2022-01-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法
CN117018170A (zh) * 2016-06-20 2023-11-10 Isa制药有限公司 肽疫苗制剂
JP6292267B2 (ja) * 2016-09-13 2018-03-14 ニプロ株式会社 ドセタキセル製剤
JP7182794B2 (ja) * 2017-08-31 2022-12-05 国立大学法人東北大学 リンパ行性薬剤送達法に有効な薬剤を含む溶液の適正な浸透圧域
JP2018115178A (ja) * 2018-03-15 2018-07-26 ニプロ株式会社 ドセタキセル製剤
KR20210078505A (ko) 2018-10-16 2021-06-28 유에스 나노 푸드 앤 드럭 인코포레이티드 종양내 주사 제형
KR102401546B1 (ko) * 2020-03-25 2022-05-27 주식회사 보령 탁산, 이의 약학적으로 허용되는 염, 또는 그의 수화물을 함유하는 안정성이 향상된 신규 약제학적 제형
US11752165B2 (en) 2020-04-13 2023-09-12 US Nano Food & Drug, Inc Basic chemotherapeutic intratumour injection formulation
WO2022038226A1 (en) * 2020-08-19 2022-02-24 Mundipharma International Corporation Limited Etoposide toniribate formulation
EP4233837A1 (de) * 2022-02-24 2023-08-30 CellAct Pharma GmbH Feste und orale etoposid-toniribat-zusammensetzungen

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US5714512A (en) 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
FR2678833B1 (fr) 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
US5698582A (en) 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
AU5553894A (en) * 1992-11-27 1994-06-22 F.H. Faulding & Co. Limited Injectable taxol composition
DE69320206T2 (de) * 1992-11-27 1999-02-11 Napro Biotherapeutics Inc Paclitaxel enthaltende injizierbare zusammensetzung
FR2698543B1 (fr) 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
CN1209059A (zh) * 1995-12-21 1999-02-24 基因实验室技术有限公司 紫杉烷类组合物及方法
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
US6040330A (en) * 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
US6380405B1 (en) * 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
EP1246608A4 (de) * 2000-01-05 2005-05-18 Imarx Therapeutics Inc PHARMAZEUTISCHE ZUBEREITUNGEN ZUR VERABREICHUNG VON WIRKSTOFFEN MIT GERINGER WASSERLöSLICHKEIT
WO2001072300A1 (en) * 2000-03-24 2001-10-04 Baker Norton Pharmaceuticals, Inc. Uses of metal salts to stabilize taxane-based compositions
WO2002043765A2 (en) * 2000-11-28 2002-06-06 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
EP1365759A2 (de) * 2001-01-18 2003-12-03 PHARMACIA & UPJOHN COMPANY Paclitaxel-enthaltende chemotherapeutische mikroemulsionen mit verbesserter oraler bioverfügbarkeit
AU2003233653B2 (en) * 2002-05-23 2008-08-07 Umd, Inc. Compositions and method for transmucosal drug delivery and cryoprotection

Also Published As

Publication number Publication date
EP2308467A2 (de) 2011-04-13
EP2308467A3 (de) 2011-06-22
US20110152360A1 (en) 2011-06-23
EP2138164A1 (de) 2009-12-30
EP1904052A4 (de) 2008-12-10
EP1904052A1 (de) 2008-04-02
CA2611592A1 (en) 2006-12-21
JP2008543789A (ja) 2008-12-04
US20090118354A1 (en) 2009-05-07
TW200800159A (en) 2008-01-01
WO2006133510A1 (en) 2006-12-21
IL187957A0 (en) 2011-07-31
KR20080030024A (ko) 2008-04-03

Similar Documents

Publication Publication Date Title
SG162798A1 (en) Liquid pharmaceutical formulations of docetaxel
ZA200801575B (en) Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily
NZ593110A (en) pteridinone derivatives as MODULATORS OF TOLL-LIKE RECEPTORS
ZA200900345B (en) Preparation of pharmaceutical formulations
AU2008347158A8 (en) Oral pharmaceutical dosage forms
MX2010014234A (es) Compuestos pirazol 436.
IL195237A0 (en) Conjugates of aziridinyl-epothilone analogs and pharmaceutical compositions comprising same
EA200901319A1 (ru) Композиции для назального введения
BR112012002080A2 (pt) formulações farmacêuticas estáveis altamente concentradas de um anticorpo anti-her2 farmaceuticamente ativo, uso de uma formulação, dispositivo de injeção e kit
SI2046298T1 (sl) Farmacevtska odmerna oblika, ki vsebuje farmacevtsko sprejemljiv solubilizirni sestavek
UA115131C2 (uk) Сполуки боронатного ефіру і його фармацевтичні рецептури
ZA200903929B (en) Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
EP1660043A4 (de) Formulierung mit sofortiger freisetzung von säurelabilen pharmazeutischen zusammensetzungen
EP1993518A4 (de) Dosierungsformen zur verabreichung von arzneimittelkombinationen
EP1933760A4 (de) Zusammensetzungen und verfahren zur verabreichung von rapamycin-analoga mit paclitaxel unter verwendung von medizinprodukten
GEP20146098B (en) 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their usage as pde9a modulators
EP1624855A4 (de) Pharmazeutische zusammensetzungen und dosierformen zur verabreichung von hydrophoben arzneimitteln
MX346879B (es) Formulaciones de ketorolaco listas para su uso.
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
RS54438B1 (en) PHARMACEUTICAL DOSAGE FORM CONTAINING 6`-FLUORO- (N-METHYL-OR N, N-DIMETHYL) - 4-PHENYL-4`, 9`-DIHYDRO-3`H-SPIRO [CYCLOHEXANE-1,1`-PIRANO [3,4, B] INDOL] -4-AMINE
IL180031A0 (en) Stable pharmaceutical formulations of benzimidazole compounds
JO2814B1 (en) Combined antiviral tumor-causing mixture
SG158863A1 (en) Intravenous formulations of pde-5 inhibitors
EP1877004A4 (de) Zusammensetzungen und verfahren zur verabreichung von rapamycin-analoga mit medizinprodukten für langzeitwirkung
EP2361083A4 (de) Zusammensetzung zur behandlung von epithelgewebe